Clinical Trial Update: Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of prime-boost vaccination strategies using an H5N1 influenza vaccine adjuvanted with AS03 or MF59; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Subtype H5n1

Drugs mentioned

• AS03
• H5Nx influenza vaccine
• MF59

Snippet

Sponsor: Biomedical Advanced Research and Development Authority | Conditions: Influenza A Virus, H5N1 Subtype | Phase 2 | Status: COMPLETED | Results posted: 2020-07-14